These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 6987190

  • 1. Immunobiology of carcinoma of the prostate.
    Catalona WJ.
    Invest Urol; 1980 Mar; 17(5):373-7. PubMed ID: 6987190
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prostate cancer vaccines: current status.
    Hwang LC, Fein S, Levitsky H, Nelson WG.
    Semin Oncol; 1999 Apr; 26(2):192-201. PubMed ID: 10597730
    [Abstract] [Full Text] [Related]

  • 6. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C, Sanda MG.
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
    Dannull J, Diener PA, Prikler L, Fürstenberger G, Cerny T, Schmid U, Ackermann DK, Groettrup M.
    Cancer Res; 2000 Oct 01; 60(19):5522-8. PubMed ID: 11034097
    [Abstract] [Full Text] [Related]

  • 12. Standard treatments induce antigen-specific immune responses in prostate cancer.
    Nesslinger NJ, Sahota RA, Stone B, Johnson K, Chima N, King C, Rasmussen D, Bishop D, Rennie PS, Gleave M, Blood P, Pai H, Ludgate C, Nelson BH.
    Clin Cancer Res; 2007 Mar 01; 13(5):1493-502. PubMed ID: 17332294
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
    Katzenwadel A, Schleer H, Gierschner D, Wetterauer U, Elsässer-Beile U.
    Anticancer Res; 2000 Mar 01; 20(3A):1551-5. PubMed ID: 10928069
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
    Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, Nelson WG.
    Cancer Res; 1999 Oct 15; 59(20):5160-8. PubMed ID: 10537292
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas.
    Lum HE, Miller M, Davol PA, Grabert RC, Davis JB, Lum LG.
    Anticancer Res; 2005 Oct 15; 25(1A):43-52. PubMed ID: 15816517
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.